JSP Pharmaceutical Manufacturing (Thailand) Public Past Earnings Performance
Past criteria checks 2/6
JSP Pharmaceutical Manufacturing (Thailand) Public's earnings have been declining at an average annual rate of -45.6%, while the Pharmaceuticals industry saw earnings growing at 10.5% annually. Revenues have been growing at an average rate of 18.2% per year. JSP Pharmaceutical Manufacturing (Thailand) Public's return on equity is 2%, and it has net margins of 3.1%.
Key information
-45.6%
Earnings growth rate
-52.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 18.2% |
| Return on equity | 2.0% |
| Net Margin | 3.1% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How JSP Pharmaceutical Manufacturing (Thailand) Public makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 703 | 22 | 180 | 0 |
| 31 Mar 24 | 628 | -6 | 170 | 0 |
| 31 Dec 23 | 594 | -1 | 163 | 0 |
| 30 Sep 23 | 585 | 3 | 159 | 0 |
| 30 Jun 23 | 518 | -6 | 152 | 0 |
| 31 Mar 23 | 506 | -4 | 154 | 0 |
| 31 Dec 22 | 467 | -17 | 155 | 0 |
| 30 Sep 22 | 419 | -24 | 149 | 0 |
| 30 Jun 22 | 419 | -13 | 135 | 0 |
| 31 Mar 22 | 419 | 11 | 118 | 0 |
| 31 Dec 21 | 429 | 30 | 103 | 0 |
| 30 Sep 21 | 422 | 32 | 96 | 0 |
| 30 Jun 21 | 421 | 32 | 95 | 0 |
| 31 Mar 21 | 433 | 29 | 98 | 0 |
| 31 Dec 20 | 463 | 31 | 100 | 0 |
| 31 Mar 20 | -234 | 22 | -17 | 0 |
| 31 Dec 19 | 369 | 24 | 82 | 0 |
| 31 Dec 18 | 352 | 12 | 79 | 0 |
| 31 Dec 17 | 440 | 30 | 77 | 0 |
Quality Earnings: JSP-R has high quality earnings.
Growing Profit Margin: JSP-R became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: JSP-R's earnings have declined by 45.6% per year over the past 5 years.
Accelerating Growth: JSP-R has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: JSP-R has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6.4%).
Return on Equity
High ROE: JSP-R's Return on Equity (2%) is considered low.